Hair Loss News and Research

RSS

Scientists grow hair on bald mice

Japanese researchers have successfully regrown hair on a bald mouse. This could mean hair related solutions for many men and women with baldness in future.

22 Apr 2012

Study pinpoints mechanism by which spindle checkpoint proteins bind chromosomes

The development of more effective cancer drugs could be a step nearer thanks to the discovery, by scientists at Warwick Medical School, of how an inbuilt 'security check' operates to guarantee cells divide with the correct number of chromosomes.

21 Apr 2012

UTHealth researcher studies novel cell therapy to prevent GVHD

A researcher at The University of Texas Health Science Center at Houston (UTHealth) is studying a novel cell therapy that could help avoid autoimmune problems after stem cell transplantation, as well as potentially treat other autoimmune diseases.

17 Apr 2012

UC professor to show new anticancer agent at ACS Spring 2012 meeting

Advances in chemotherapy have dramatically improved the outlook for many cancer patients, but the side effects of this treatment are daunting. A new generation of chemotherapy drugs with fewer side effects is the goal of Edward J. Merino, assistant professor of chemistry at the University of Cincinnati.

27 Mar 2012

Male pattern baldness causes discovered

Most men start to go bald in middle age, with about 80% of men having some hair loss by the age of 70. Male pattern baldness is the most common type of hair loss for men, the National Institute of Health said. Symptoms include a thinning of hair at the hairline, eventually creating a U-shaped or horseshoe pattern of hair on both sides of the head. The male sex hormone testosterone plays a key role, as do genetic factors. They cause the hair follicles to shrink, eventually becoming so small that they are invisible, leading to the appearance of baldness. While treatment is not necessary, side effects including psychological stress and loss of self-esteem due to change in appearance can be experienced.

25 Mar 2012

Issues and treatments of chronic skin wounds

The skin is the body's largest organ and an indispensable part of the immune system. As the body's outermost line of defense against microbes, the skin provides important protection against potentially toxic environmental elements. One subset of immune cells, thymus-derived T-cells play an important role in the skin's response to injury, particularly with respect to wound healing.

21 Mar 2012

Styling practices linked with hair or scalp diseases among African Americans

Styling practices can lead to serious hair and scalp diseases for some African Americans, says Henry Ford Hospital dermatologist Diane Jackson-Richards, M.D.

20 Mar 2012

Vitamin A daily dose may help prevent skin cancer: Study

A study has shown that a daily vitamin pill could help prevent skin cancer - particularly among women. Scientists say taking food supplements containing vitamin A can make people less likely to develop melanoma, the deadliest form of the disease.

4 Mar 2012

Restoration Robotics ARTAS hair transplantation system receives Canadian Medical Device License

Restoration Robotics, Inc., a privately-held medical device company, today announced that its revolutionary ARTAS System has received a Canadian Medical Device License and can now be marketed and sold within Canada.

27 Feb 2012

Skin cancer drug may prolong survival in advanced cases: Study

Researchers say 132 patients in the U.S. and Australia who were given the drug vemurafenib gained several extra months of life. The study published in the New England Journal of Medicine found that those on the drug lived an average of 16 months, compared with nine months on conventional treatment.

26 Feb 2012

Vemurafenib nearly doubles survival for patients with metastatic melanoma

Investigators from Vanderbilt-Ingram Cancer Center (VICC) and 12 other centers in the United States and Australia have found that a new drug for patients with metastatic melanoma nearly doubled median overall survival.

23 Feb 2012

New triple-therapies found cost-effective for chronic hepatitis C patients with advanced liver disease

A towering $60,000 bill, a year of fierce, flu-like symptoms and a running risk of depression are among the possible costs of two new hepatitis C treatments. But according to Stanford University health policy researchers, they might be worth it.

21 Feb 2012

EC approves Plexxikon's Zelboraf to treat BRAF mutation-positive MM

Plexxikon Inc., a member of Daiichi Sankyo Group, today announced that the European Commission has approved Zelboraf (vemurafenib) for the monotherapy treatment of adult patients with BRAFV600 mutation-positive unresectable or metastatic melanoma.

20 Feb 2012

Roche’s skin cancer drug Erivedge gets FDA nod

The Food and Drugs Administration (FDA) this Monday approved a pill that treats the most common type of skin cancer, basal cell carcinoma.

31 Jan 2012

FDA approves Genentech's Erivedge for treatment of BCC

Genentech, a member of the Roche Group, today announced that Erivedge (vismodegib) capsule was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with a type of skin cancer, called basal cell carcinoma (BCC), that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation.

31 Jan 2012

Genentech receives FDA approval for Erivedge to treat basal cell carcinoma

Today, Erivedge (vismodegib) was approved by the U.S. Food and Drug Administration to treat adult patients with basal cell carcinoma, the most common type of skin cancer. The drug is intended for use in patients with locally advanced basal cell cancer who are not candidates for surgery or radiation and for patients whose cancer has spread to other parts of the body.

31 Jan 2012

UHCMC now offers HITEC for women with gynecologic cancers

Patients with gynecologic cancer have new hope in a novel technology now offered at the Seidman Cancer Center at University Hospitals (UH) Case Medical Center. A team of cancer specialists, led by Robert DeBernardo, MD, is among the first in the nation to launch a dedicated program using Hyperthermic Intraperitoneal Chemotherapy (HIPEC) to treat ovarian, endometrial and select other cancers.

21 Jan 2012

Researchers discover HS1.2 enhancer as the cause of SLE

A "genetic accelerator" is responsible for the most severe cases of Lupus (systemic lupus erythemathosus), an autoimmune disease: the accelerator, called enhancer HS1.2, speeds up the activity of some critical genes of the immune system involved in the disease.

17 Jan 2012

CMS assigns J-code for Eisai's Halaven Injection to treat breast cancer

Eisai Inc. announced today that the Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code for Halaven (eribulin mesylate) Injection.

4 Jan 2012

FDA accepts Genentech's vismodegib NDA for review

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review Genentech's new drug application (NDA) for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

9 Nov 2011